Abstract: Methods for treating glioblastoma in a subject comprising administering to the subject an inhibitor of a Src family kinase. Methods for inhibiting the migration of a glial cell comprising contacting the glial cell with an inhibitor of a Src family kinase or reducing the expression of a Src family kinase in the glial cell. Methods for reducing or inhibiting tumor formation in a subject comprising administering to the subject an inhibitor of a Src family kinase or administering an oligonucleotide or a gene editing system that reduces the expression of a Src family kinase within a cell. Ex vivo co-culture systems comprising a Dorsal Root Ganglion (DRG) axon-oligodendrocyte and a gliomal cell. Methods for identifying an inhibitor of glial cell migration or movement. Methods for treating glioblastoma and for isolating pseudopodia of a gliomal cell and for identifying RNA present therein.
Type:
Application
Filed:
October 28, 2016
Publication date:
November 29, 2018
Inventors:
Nikolaos Tapinos, Atom Sarkar, Jennifer Ness-Myers
Abstract: Described herein are compositions, including an oral dosage regimen, for the treatment of NMDAR-related neuropsychiatric disorders such as depression and obsessive-compulsive disorder and that includes an NMDAR antagonist, such as D-cycloserine formulated to produce plasma levels in excess of 25 microgram/mL, combined with more recently developed antidepressants.
Abstract: Methods of treating diseases caused by cell division or that are treated by inhibiting mitosis by administering two doses of an inhibitor of mitosis between the biologically effective dose and the maximum tolerated dose in a dosing cycle that allows for the recovery or subsiding of side effects, wherein the second dose is administered 24 to 48 hours after the first dose.
Type:
Application
Filed:
June 5, 2018
Publication date:
November 29, 2018
Applicant:
Array BioPharma Inc.
Inventors:
Brian J. Tunquist, Duncan HL. Walker, Richard D. Woessner
Abstract: Formulations for treating depressive disorders and methods for treating depressive disorders using gaboxadol or a pharmaceutically acceptable salt thereof are provided.
Abstract: Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided. The methods provide therapeutic compositions that may be used to improve one or more symptoms of the developmental disorder.
Abstract: Provided herein are methods for determining the efficacy of treatment for polycystic kidney disease (PKD) in a patient, diagnosing PKD in a patient, staging PKD in a patient, and monitoring PKD in a patient. These methods include determining a single or multiple levels of AMBP. Also provided are kits that include an antibody specifically binds to AMBP protein and at least one antibody that specifically binds to an additional marker of PKD.
Type:
Application
Filed:
November 15, 2016
Publication date:
November 29, 2018
Inventors:
Nikolai Bukanov, Sarah Moreno, Timothy E. Weeden
Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.
Type:
Application
Filed:
June 24, 2016
Publication date:
November 29, 2018
Inventors:
Satish NADIG, Carl ATKINSON, Ann-Marie BROOME, Suraj K. DIXIT
Abstract: Described are a group of isoxazol-3(2H)-one analogues and their use in topical formulations for the treatment and prophylaxis of dermatological disorders.
Abstract: The invention discloses a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and a preparation method and application thereof. The amphiphilic hypocrellin derivative substituted by a group containing PEG, a quaternary ammonium salt or the like prepared according to the invention has an obvious red shift in its absorption spectrum and a significantly enhanced molar extinction coefficient, compared with the parent hypocrellin, can efficiently produce singlet state oxygen and other reactive oxygen species under photosensitive conditions; has different amphiphilicities and increased biocompatibility with cells or tissues by regulating its hydrophilicity and hydrophobicity; can meet the requirements of different clinical drugs, and solves the requirements of different drug delivery methods for different drug hydrophilicity and lipophilicity.
Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
Type:
Application
Filed:
July 23, 2018
Publication date:
November 29, 2018
Inventors:
Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
Abstract: The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
Type:
Application
Filed:
July 30, 2018
Publication date:
November 29, 2018
Inventors:
Huai-Hung Kao, Anand R. Baichwal, Troy McCall, David Lee
Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxymorphone (4,5-?-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxymorphone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxymorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Type:
Application
Filed:
August 3, 2018
Publication date:
November 29, 2018
Inventors:
Travis Mickle, Sven Guenther, Sanjib Bera, Jaroslaw Kanski, Andrea Martin
Abstract: Compositions and methods for the treatment of Charcot-Marie-Tooth disease and related disorders. Also provided are combination therapies for treating this disease by decreasing PMP22 expression in a subject.
Type:
Application
Filed:
August 6, 2018
Publication date:
November 29, 2018
Inventors:
Daniel COHEN, Ilya CHUMAKOV, Oxana GUERASSIMENKO, Serguei NABIROCHKIN
Abstract: Methods for treating Cushing's Syndrome and other conditions associated with excessive cortisol production such as Cushing's Disease, ectopic adrenocorticotropic hormone secretion, ectopic corticotropin-releasing hormone secretion, adrenal-dependent Cushing's Syndrome, adrenal adenoma, adrenal autonomy, or any other condition associated with persistent or recurrent endogenous hypercortisolemia are provided. The methods include administration of a 2S,4R ketoconazole enantiomer substantially free of the 2R,4S enantiomer to patients according to a dosing titration schedule or at an effective amount. Treatment methods according to the invention may be safer and more effective than treatment using racemic ketoconazole.
Abstract: The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X1, X6, X8, Q1, Q2, Q3, Q4, Q5, Q6, Ring A, Ring B, W, W?, R2, R3, R, R?, m, n and q are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
Abstract: The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R2, R3, R4 and R5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.
Type:
Application
Filed:
November 4, 2016
Publication date:
November 29, 2018
Inventors:
Xuehai Wang, Yong Xu, Xijun Sheng, Xiaolin Zhang, Hangui Xia, Zhongwen Yang, Yang Yue, Lu Huang, Qiang Xiao
Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.
Type:
Application
Filed:
July 30, 2018
Publication date:
November 29, 2018
Inventors:
Giuseppe ALVARO, Anne Decor, Stefano fontana, Dieter Hamprecht, Charles Large, Agostino Marasco
Abstract: The invention relates to pharmacology and can be used for treating liver diseases of various etiologies, inter alia, in combination with other preparations. Claimed is a drug with hepatoprotective activity comprised of 3-(4-bromophenyl)-6,6-dihydroxy-5-hydroxyiminohexahydro-2,4-pyrimidinedione and salts thereof of general formula (I), where X is selected from the group: H, Na, K, or from the group of hydroxyalkylammonia derivatives of general formula (II), where R1, R2 are selected from the group: H, CH3, CH2CH3, CH2CH2OH; R3 is selected from the group: H, CH2OH; and n=1, 2; the drug can be prepared in the form of tablets or capsules for enteral administration; or in the form of a liquid or lyophilized substance for parenteral administration; or in the form of rectal suppositories; or in the form of capsules or tablets, or sweets for sucking; and may additionally contain the hepatoprotector Heptral; or the hepatoprotector Essentiale; or the hepatoprotector ursodeoxycholic acid.
Type:
Application
Filed:
March 23, 2016
Publication date:
November 29, 2018
Inventors:
Viktor Veniaminovich Tets, Georgy Viktorovich Tets
Abstract: A method for treating cancer in patients with creatinine clearance of 15 mL/min or more and less than 30 mL/min, including dividing a combination drug containing ?,?,?-trifluorothymidine (FTD) and 5-chloro-6-[(2-iminopyrrolidine-1-yl)methyl]pyrimidine-2,4(1H,3H)-dione hydrochloride in a molar ratio of 1:0.5, in a dose of 30 to 50 mg/m2/day as FTD-equivalent, into two to four times a day, and orally administering it to the patient.
Abstract: Methods of treating a head and neck cancer are disclosed.
Type:
Application
Filed:
January 17, 2018
Publication date:
November 29, 2018
Inventors:
Chris Hendrik Boshoff, Timothy Robert Fenton, Matthias Alexander Lechner, Philip James Stephens, Matthew J. Hawryluk, Garrett Michael Frampton, Roman Yelensky
Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Abstract: The present invention provides a method of providing adjuvant treatment to a human patient which comprises administering to such a patient therapeutically effective doses of debrafenib and trametinib for a time period sufficient to increase relapse-free survival (RFS).
Abstract: Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.
Type:
Application
Filed:
June 7, 2016
Publication date:
November 29, 2018
Inventors:
Stefan WERNER, Stefanie MESCH, Nico BRÄUER, Elisabeth POOK, Henrik DAHLLÖF, Reinhard NUBBEMEYER, Maren OSMERS, Bernd KALTHOF
Abstract: The present invention relates to a highly convergent method for the synthesis and purification of ceftolozane and intermediates starting from 7-aminocephaiosporanic acid (7-ACA).
Type:
Application
Filed:
September 7, 2016
Publication date:
November 29, 2018
Applicant:
Sandoz AG
Inventors:
Michael Fischer, Wolfgang Felzmann, Ronny Huetz, Martin Langner, Birgit Endl
Abstract: This invention captures and teaches the high-level method of combining doses of medications in unconventionally substandard amounts for the cooperative treatment of medical pathologies with the end product of a pharmaceutical composition. By combining multiple medications, each treating the same disease process and each in a calculated substandard dosage, it is rational to allow for greater comprehensive efficacy while simultaneously bypassing conventional side-effects, clinically significant medication interactions, and other potentially unforeseen deleterious effects, all because the dosage composition is small enough individually and collaborative chemical diversity manifests favorable kinetic dynamics, thereby mitigating unwanted drug effects while enhancing the targeted indication.
Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.
Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
Type:
Application
Filed:
December 28, 2017
Publication date:
November 29, 2018
Inventors:
Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
Abstract: The present disclosure relates to methods and products for reducing the viability of microorganisms, and to methods and products for preventing and/or treating microorganism infections. Certain embodiments of the present disclosure provide a method for reducing viability of a microorganism. The method comprises exposing the microorganism to an effective amount of an iron chelator and subsequently exposing the microorganism to an effective amount of a non-iron porphyrin, thereby reducing the viability of the microorganism.
Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Abstract: Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
Type:
Application
Filed:
May 23, 2018
Publication date:
November 29, 2018
Applicant:
KYTHERA BIOPHARMACEUTICALS, INC.
Inventors:
Robert M. Moriarty, Nathaniel E. David, Nadir Ahmeduddin Mahmood
Abstract: The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.
Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.
Type:
Application
Filed:
May 8, 2018
Publication date:
November 29, 2018
Applicant:
Amygdala Neurosciences, Inc.
Inventors:
Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
Abstract: A method of preparing rumen-protected carbohydrates for use in ruminant feeds by inducing the Maillard reaction between a reducing carbohydrate source and a protein source under reduced pressure conditions is disclosed. Products made by the process, and methods for maintaining or restoring blood glucose levels to within the normal reference range for ruminants, especially during transition or under heat stress are also disclosed.
Type:
Application
Filed:
May 24, 2018
Publication date:
November 29, 2018
Applicant:
Rupca LLC
Inventors:
Juan Pablo Russi, Paula Figuiera Artieda, Alejandro Ramon Castillo
Abstract: Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods. Methods and compositions are provided for the treatment of diseases or disorders associated with mitochondrial dysfunction. The invention relates to methods for treatment and prevention of cancer by administering agents that increase levels of NAD+, such as NAD+ precursors or agents involved in NAD+ biosynthesis.
Type:
Application
Filed:
December 7, 2017
Publication date:
November 29, 2018
Applicants:
President and Fellows of Harvard College, NewSouth Innovations Pty Limited
Inventors:
David A. Sinclair, Ana P. Gomes, Lindsay Wu
Abstract: Disclosed herein are antisense oligonucleotide sequences against IL-34 and methods for treating inflammatory diseases, such as inflammatory bowel disease, and/or fibrosis, associated with elevated activity or expression of IL-34. Also disclosed are pharmaceutical compositions containing an IL-34 antisense oligonucleotide useful for treating inflammatory diseases and/or fibrosis and manufacture of medicaments containing a disclosed IL-34 antisense oligonucleotide to be used in treating inflammatory diseases and/or fibrosis.
Type:
Application
Filed:
November 25, 2016
Publication date:
November 29, 2018
Applicant:
Nogra Pharma Limited
Inventors:
Marie McNulty, Francesca Viti, Salvatore Bellinvia
Abstract: Tipifarnib or a tipifarnib derivative is used to treat HDV infection as a monotherapy or in combination with an interferon and/or boosting agent such as a CYP3A4 inhibitor such as ritonavir and cobicistal. This invention arises in part out of the surprising discoveries that not all prenyltransferase inhibitors are efficacious in treating HDV infection and that tipifarnib (Rl 15777) and tipifarnib derivatives such as R208176 can be administered at a dose efficacious in humans. This invention accordingly provides a method of inhibiting HDV replication in a human subject known to be co-infected with HBV and HDV by administering a therapeutically effective dose of tipifarnib, R208176 and other therapeutically effective tipifarnib derivatives and pharmaceutically acceptable salts and other forms.
Type:
Application
Filed:
December 3, 2015
Publication date:
November 29, 2018
Applicant:
Eiger BioPharmaceuticals, Inc.
Inventors:
David Cory, Ingrid Choong, Jeffrey S. Glenn
Abstract: A method of treatment of viral infection in a subject comprising administering to the subject a copolymer comprising an acrolein derived segment or a polyacrolein oligomer segment and a polyalkylene glycol oligomer segment, the copolymer having a molecular weight of no more than 1500 Daltons.
Type:
Application
Filed:
February 17, 2017
Publication date:
November 29, 2018
Inventors:
Graham John Hamilton MELROSE, Michele Keryn DILIZIA
Abstract: Embodiments described herein generally relate to systems and methods for treatments using xenon and hydrogen. In some embodiments, liquids comprising xenon and hydrogen are provided. Such liquids may be useful, for example, for the treatment of animal and human diseases, for improvement in athletic performance, for the enhancement of the overall health of a subject, or the like. The liquids (e.g., aqueous solutions) and articles described herein may be administered to a subject, e.g., drunk by a subject. Some embodiments relate to liquids disposed within a container (e.g., a sealed container), such that the liquid comprises hydrogen gas and a noble gas dissolved or otherwise contained (e.g., infused) in the liquid. In certain embodiments, the hydrogen gas and/or noble gas may be present in the liquid at a particular concentration (e.g., a physiologically relevant concentration).
Abstract: The present invention concerns a method for treatment of traumatic brain injury (TBI) in a human or non-human animal subject, comprising administering stem or progenitor cells to the subject, such as mesenchymal stromal cells; and administering one or more PPAR? agonists, such as pioglitazone (PG), to the subject before, during, and/or after administration of the stem or progenitor cells. Another aspect of the invention concerns a pharmaceutical composition useful for treating TBI, the composition comprising stem cells or progenitor cells, such as mesenchymal stromal cells, and one or more PPAR? agonists, such as PG.
Type:
Application
Filed:
May 23, 2018
Publication date:
November 29, 2018
Applicant:
UNIVERSITY OF SOUTH FLORIDA
Inventors:
SUBHRA MOHAPATRA, SHYAM S. MOHAPATRA, MAHASWETA DAS
Abstract: The present invention provides improved methods and compositions based on microvesicles for the treatment of various diseases, disorders and conditions. In particular, the present invention encompasses the recognition that microvesicles contain specific microRNAs which may function as intercellular regulators involved in cell or tissue regeneration, remodeling, reconstruction, reprogramming or transdifferentiation. Thus, among other things, the present invention provides methods and compositions based on microvesicles and/or associated microRNAs that provide more predictable and effective therapeutic results.
Abstract: This document provides methods and materials for treating nerve injuries and/or neurological disorders. For example, compositions including an amnion tissue preparation and/or a stem cell preparation as well as methods for using such compositions to treat a nerve injuries and/or neurological disorders are provided.
Abstract: Cells derived from postpartum tissue and products thereof having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.
Type:
Application
Filed:
August 6, 2018
Publication date:
November 29, 2018
Applicant:
DePuy Synthes Products, Inc.
Inventors:
Laura J. Brown, Alexander M. Harmon, Anna Gosiewska
Abstract: The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.
Type:
Application
Filed:
August 6, 2018
Publication date:
November 29, 2018
Inventors:
Russell A. Kern, Rodolfo Gonzalez, Ibon Garitaonandia
Abstract: The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject.
Type:
Application
Filed:
August 6, 2018
Publication date:
November 29, 2018
Inventors:
Russell A. Kern, Rodolfo Gonzalez, Ibon Garitaonandia
Abstract: The present invention relates to the use of eggshell membrane compositions to activate levels of nuclear factor kappa-light-chain-enhancer of activated B cells (“NF-?B”) in the gut of a host in need thereof and methods of treating conditions related to NF-?B dysregulation. The herein invention provides a method for activating NF-?B in the gut of a host in need thereof. The method comprises orally administering an effective amount of a composition consisting essentially of eggshell membrane, and/or eggshell membrane isolates and/or eggshell membrane hydrolysates for activation of NF-?B to the host.
Abstract: A parenteral delivery device and method of delivering a multi-system treatment to a centralized location where the delivery device includes at least an inner compartment encapsulating a first system and an outer compartment encapsulating a second system and the first and second systems have different mechanisms of action for use in the treatment of vaginal infection.
Abstract: The present disclosure relates to recombinant viral vectors for the treatment and prevention of cancer. Oncolytic viral vectors incorporate one or more of the following features: viral replication restriction by insertion of tumor-suppressive microRNA (miRNA) target sequences into the viral genome; disruption of oncogenic miRNA function; cancer microenvironment remodeling; and cancer cell targeting by incorporation of protease-activated antibodies into the viral particle.
Type:
Application
Filed:
July 27, 2018
Publication date:
November 29, 2018
Inventors:
Kenneth P. GREENBERG, Mitchell H. FINER